Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …

For decades, the hypothesis that brain deposition of the amyloid β protein initiates
Alzheimer's disease has dominated research and clinical trials. Targeting amyloid β is …

Introduction As clinical trials move toward earlier intervention, we sought to redefine the β-
amyloid (Aβ)-PET threshold based on the lowest point in a baseline distribution that robustly …

Alzheimer's disease (AD) is a multifactorial and heterogeneous disorder, which makes early
detection a challenge. Studies have attempted to combine biomarkers to improve AD …

Objective To understand the time course of β-amyloid (Aβ) deposition in the brain, which is
crucial for planning therapeutic trials of Aβ-lowering therapies in Alzheimer disease (AD) …

Objective To develop and evaluate a model for staging cortical amyloid deposition using
PET with high generalizability. Methods Three thousand twenty-seven individuals (1,763 …

Background and Objectives Alzheimer disease (AD) clinical trials are moving earlier in the
disease process according to emerging signs of β-amyloid (Aβ) and tau pathology. If early …

Brain proteins function in their soluble, native conformation and cease to function when
transformed into insoluble aggregates, also known as amyloids. Biophysically, the soluble-to …

Introduction: We investigated whether monthly assessments of a computerized cognitive
composite (C3) could aid in the detection of differences in practice effects (PE) in clinically …

Objective To clarify the preclinical stage of Alzheimer's disease by estimating when β‐
amyloid accumulation first becomes associated with changes in cognition. Methods Here we …